Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Biocompatible Patch Repairs Heart Damage in Rat Model

By Gerald M. Slutzky, PhD
Posted on 13 Dec 2016
A team of Australian and British bioengineers has developed an electrically active biocompatible insert that can repair damage to electro-responsive tissues, such as the brain, heart, and nervous system without need of sutures.

Conducting polymers (CPs) are being considered as components of this type of biocompatible insert because of their intrinsic electroactive and flexible nature. More...
However, their clinical application has been largely hampered by their short operational time due to a decrease in their electronic properties.

To circumvent this problem investigators at the University of New South Wales (Sydney, Australia) and Imperial College London (United Kingdom) developed a novel CP scaffolding by growing polyaniline (PANI) doped with phytic acid on the surface of a chitosan film. Chitosan is a polysaccharide found in crab shells that is often used as a food additive; polyaniline is a conducting polymer; and phytic acid is a substance found in plants that is added to the polyaniline to switch it to its conducting state.

The investigators reported in the November 30, 2016, online edition of the journal Science Advances that the strong chelation between phytic acid and chitosan led to a conductive patch with retained electroactivity, low surface resistivity, and oxidized form after two weeks of incubation in physiological medium.

Ex vivo experiments revealed that the conductive nature of the patch had an immediate effect on the electrophysiology of the heart, while preliminary in vivo experiments in a rat model showed that the conductive patch did not induce proarrhythmogenic activities in the heart while it improved the conduction of electrical impulses across heart scar tissue.

"Our suture-less patch represents a big advance," said first author Dr. Damia Mawad, lecturer in materials science and engineering at the University of New South Wales. "We have shown it is stable and retains it conductivity in physiological conditions for more than two weeks, compared with the usual one day of other designs. No stitches are required to attach it, so it is minimally invasive and less damaging to the heart, and it moves more closely with the heart's motion. We envisage heart attack patients eventually having patches attached as a bridge between the healthy and the scar tissue, to help prevent cardiac arrhythmia. However, our patch is at the very early stages of this research. This technology can now be used for basic research to gain insights into the interface between the material and tissue."

Related Links:
University of New South Wales
Imperial College London

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.